2021 annual financial data
Inhibikase Therapeutics 2021 Operating cash flow margin
Direct answer
Operating cash flow margin was -461.11%.
Operating income was -14,766,140 USD and net income was -14,805,986 USD.
Operating cash flow was -14,297,051 USD.
Get free Inhibikase Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 3,100,605 USD
- Operating income
- -14,766,140 USD
- Net income
- -14,805,986 USD
- Operating cash flow
- -14,297,051 USD